* Multi-center, placebo-controlled study designed to explore PROSTVAC(®) in
patients undergoing active surveillance
COPENHAGEN, Denmark - July 24, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today that the first patient has been enrolled in a new phase
2 clinical study ...
↧